Impel Pharmaceuticals Statistics
Share Statistics
Impel Pharmaceuticals has 23.9M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 23.9M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 450,985 |
| FTD / Avg. Volume | 44.04% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.68 and the forward
PE ratio is null.
Impel Pharmaceuticals's PEG ratio is
-0.13.
| PE Ratio | -0.68 |
| Forward PE | n/a |
| PS Ratio | 6.95 |
| Forward PS | n/a |
| PB Ratio | -1.99 |
| P/FCF Ratio | -0.93 |
| PEG Ratio | -0.13 |
Financial Ratio HistoryEnterprise Valuation
Impel Pharmaceuticals has an Enterprise Value (EV) of 78.45M.
| EV / Sales | 6.2 |
| EV / EBITDA | -0.94 |
| EV / EBIT | -0.84 |
| EV / FCF | -0.83 |
Financial Position
The company has a current ratio of 3.6,
with a Debt / Equity ratio of -1.16.
| Current Ratio | 3.6 |
| Quick Ratio | 3.22 |
| Debt / Equity | -1.16 |
| Debt / EBITDA | -0.62 |
| Debt / FCF | -0.54 |
| Interest Coverage | -6.01 |
Financial Efficiency
Return on Equity is 293.14% and Return on Invested Capital is -1440.9%.
| Return on Equity | 293.14% |
| Return on Assets | -146.18% |
| Return on Invested Capital | -1440.9% |
| Revenue Per Employee | $79,075 |
| Profits Per Employee | $-809,000 |
| Employee Count | 160 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.77 |
Taxes
| Income Tax | 23.13M |
| Effective Tax Rate | -21.75% |
Stock Price Statistics
The stock price has increased by -60.44% in the
last 52 weeks. The beta is 1.17, so Impel Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | -60.44% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 41.76 |
| Average Volume (20 Days) | 1,023,947 |
Income Statement
In the last 12 months, Impel Pharmaceuticals had revenue of 12.65M
and earned -129.44M
in profits. Earnings per share was -5.52.
| Revenue | 12.65M |
| Gross Profit | 6.16M |
| Operating Income | -83.18M |
| Net Income | -129.44M |
| EBITDA | -83.18M |
| EBIT | -92.48M |
| Earnings Per Share (EPS) | -5.52 |
Full Income StatementBalance Sheet
The company has 60.65M in cash and 51.19M in
debt, giving a net cash position of 9.47M.
| Cash & Cash Equivalents | 60.65M |
| Total Debt | 51.19M |
| Net Cash | 9.47M |
| Retained Earnings | -321.11M |
| Total Assets | 35.07M |
| Working Capital | -101.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -93.64M
and capital expenditures -1.38M, giving a free cash flow of -95.02M.
| Operating Cash Flow | -93.64M |
| Capital Expenditures | -1.38M |
| Free Cash Flow | -95.02M |
| FCF Per Share | -4.05 |
Full Cash Flow StatementMargins
Gross margin is 48.66%, with operating and profit margins of -657.48% and -1023.08%.
| Gross Margin | 48.66% |
| Operating Margin | -657.48% |
| Pretax Margin | -840.28% |
| Profit Margin | -1023.08% |
| EBITDA Margin | -657.48% |
| EBIT Margin | -657.48% |
| FCF Margin | -751.02% |
